This was such a great collaboration with @drmariespreckley.bsky.social, Dr Adrian Brown, and Dr Nikki Davis, published in @thelancetendo.bsky.social !

@imsepidemiology.bsky.social @thelancet.com

Delighted to see our latest publication in The Lancet Diabetes & Endocrinology: “Prioritising nutrition alongside paediatric obesity management medications”Congratulations to @cararuggiero.bsky.social for leading this important piece: www.thelancet.com/journals/lan...

@nytimes.com @imsepidemiology.bsky.social

@imsepidemiology.bsky.social @financialtimes.com

Weight-loss drugs and Mars bars: Novo Nordisk’s comeback bid The maker of Wegovy and Ozempic wants to learn lessons from consumer groups to crack the US market

Delighted to contribute to the latest Financial Times feature on the growing consumerisation of GLP-1 therapies and the future of obesity treatment.

It is important to remember that they remain medical interventions requiring appropriate clinical oversight, support, and equitable access.

What you need to know before taking weight-loss drugs Weight-loss drugs are not the easy solution that many people believe, especially if you hope to keep the pounds off in the long-term.

Nipping at the heels of GLP-1 weight-loss drugs is the growing concern the pounds shed will be rapidly regained.

"You don't want to have longer-term unintended consequences, like frailty and muscle loss. We don't want to replace one health concern with another."

Read – buff.ly/OTpSvPq

@imsepidemiology.bsky.social’s @drmariespreckley.bsky.social is quoted in a BBC Future’s article, highlighting concerns that a lack of behavioural and lifestyle support for those on weight-loss drugs can lead to further issues.

Read the full BBC Future – buff.ly/OTpSvPq

@haotang.bsky.social @andreadsmith.bsky.social
@amyahern.bsky.social @imsepidemiology.bsky.social

Fantastic to see this new study published in JMIR, led by our PhD student Hao Teng.

In this qualitative study, we explored how young adults interact with food and nutrition content on social media, and how this can inform the design of effective interventions.

www.jmir.org/2026/1/e89344

Delighted to contribute to this BBC Future piece out today.

Ensuring the right support is in place to optimise outcomes is critical, particularly as use increases.

www.bbc.co.uk/future/artic...

@bbcstudios.bsky.social @imsepidemiology.bsky.social

Wonderful evening presenting on the impact of the cost of living crisis on infant feeding in the first 1,000 days of life.

It has been an absolute privilege to work on this important study led by the brilliant @cararuggiero.bsky.social over the past two years. @imsepidemiology.bsky.social

Free Cambridge Festival Talk The cost-of-living crisis and the first 1,000 days of life With Dr Cara Ruggiero and Dr Marie Spreckley Thursday 26 March 2026, 6 PM Old Divinity School, St John's College, Cambridge.

What are the impacts of food insecurity during the first 1,000 days of life?

Join @cararuggiero.bsky.social & @drmariespreckley.bsky.social this Thursday at 6 PM for a free in-person Cambridge Festival talk on insights from the SPROUT study.

Register buff.ly/SRMHqfN

GLP-1 therapies work, but how do we balance clinical effectiveness with lived experience, equity, and long-term support?

Looking forward to discussing this as a keynote panel member at the Society of Behavioral Medicine Annual Meeting in Chicago on 25 April this year.

See you there!

When Weight-Loss Drugs Don’t Work

Delighted to contribute to this New York Times piece on why weight-loss medications do not work equally well for everyone: www.nytimes.com/2026/03/12/w...

Cambridge Festival logo beside a photo of a white couple holding a baby, with the header: Free Cambridge Festival talk, The cost-of-living crisis and the first 1,000 days of life, with Dr Cara Ruggiero and Dr Marie Spreckley. Thursday 26 March, 6 PM, Old Divinity School St. Johns College, Cambridge.

What is the impact of food insecurity during the first 1,000 days of life?

Join our free in-person @cambridgefestival.bsky.social talk with @cararuggiero.bsky.social & @drmariespreckley.bsky.social

26 March, 6 PM, Old Divinity School, Cambridge

Register buff.ly/HGezP5k

The researchers are:

Dr @cararuggiero.bsky.social - University of Cambridge (@cam.ac.uk)
Dr @drmariespreckley.bsky.social - @cam.ac.uk
Dr Nikki Davis - @unisouthampton.bsky.social
Dr Adrian Brown - University College London (@ucl.ac.uk)

Find out more in our blog - buff.ly/LS68rwH

Researchers from the University of Cambridge, University College London, and the University of Southampton comment on the necessity of keeping nutrition at the heart of management medications for children and adolescents.

Paediatricians in the UK are prescribing obesity management medications e.g. GLP-1s to children and adolescents for whom lifestyle interventions by themselves are not enough.

Find out more in our blog - buff.ly/LS68rwH

Cambridge Festival logo beside a photo of a white couple holding a baby, with the header: Free Cambridge Festival talk, The cost-of-living crisis and the first 1,000 days of life, with Dr Cara Ruggiero and Dr Marie Spreckley. Thursday 26 March, 6 PM, Old Divinity School St. Johns College, Cambridge.

In our free in-person @cambridgefestival.bsky.social talk @cararuggiero.bsky.social & @drmariespreckley.bsky.social will share insights from their research into impacts of food insecurity during the first 1,000 days of life.

26 March, 6 PM, Old Divinity School, Cambridge

Register buff.ly/HGezP5k

AMPLIFY AMPLIFY explores lived experiences to inform how to support individuals using, or having recently stopped using, incretin-based therapies or weight management.

Dr Spreckley @drmariespreckley.bsky.social leads the AMPLIFY study that seeks to understand how people experience next-generation weight loss therapies, to help identify the types of information and wrap-around support that are most meaningful and needed in real-world care.

buff.ly/835YqxD

(4/4)

Quote from Dr Marie Spreckley of the University of Cambridge "If nutritional care is not integrated alongside treatment, there’s a risk of replacing one set of health problems with another, through preventable nutritional deficiencies and largely avoidable loss of muscle mass. This represents a missed opportunity to support long-term health alongside weight loss."

Just 12 studies examined nutrition & diet alongside drug treatment, and as trials varied widely in their approaches to dietary advice and nutritional assessment, lacking standardised protocols and reporting, it was difficult to reach robust conclusions to inform the optimal support.

(3/4)

Image of Obesity reviews article title "Nutrition strategies for next-generation incretin therapies: a systematic scoping review of the current evidence" bu Marie spreckley, Cara F. Ruggiero and Adrian Brown. Published 07 January 2026.

In a systematic review published today, Dr Marie Spreckley, Dr Cara Ruggiero, and Dr Adrian Brown found a lack of robust evidence surrounding nutritional advice and support and its impact on calorie intake, body composition, protein adequacy, and patient experiences.

buff.ly/Az65PyP

(2/4)

Image of woman's hands holding semiglutide injection pen over plate of healthy food and cup of tea. Credit: Getty images.

New @cam.ac.uk and @ucl.ac.uk research finds people prescribed weight loss drugs such as semaglutide and tirzepatid may not receive sufficient nutritional guidance to support safe and sustainable weight loss, leaving them vulnerable to nutritional deficiencies and muscle loss.

🧵 (1/4)

AMPLIFY AMPLIFY explores lived experiences to inform how to support individuals using, or having recently stopped using, incretin-based therapies or weight management.

We have also launched the AMPLIFY study, which explores people’s lived experiences of using next-generation weight management medications, to help ensure future guidance, support and care pathways are informed by lived experience as well as clinical evidence.

studies.mrc-epid.cam.ac.uk/amplify

‪We found that nutritional adequacy and nutrition-related support are often not routinely monitored, assessed or reported, even though many studies describe changes in eating patterns and gastrointestinal symptoms that may affect diet quality, lean mass and micronutrient status.‬

In this review, we looked across published studies and trials of GLP-1 and GIP/GLP-1 receptor agonist therapies to understand how nutrition is considered alongside their use.

Nutrition Strategies for Next‐Generation Incretin Therapies: A Systematic Scoping Review of the Current Evidence Next-generation incretin therapies, including semaglutide and tirzepatide, have transformed obesity and Type 2 diabetes management. However, evidence-based nutritional strategies to support safe and ...

Delighted to share that our latest study examining nutritional considerations when using next-generation obesity weight management medications such as Ozempic and Mounjaro is now published in Obesity Reviews.
@cararuggiero.bsky.social @adrianbrown.bsky.social
onlinelibrary.wiley.com/doi/10.1111/...

In this review, we looked across published studies and trials of GLP-1 and GIP/GLP-1 receptor agonist therapies to understand how nutrition is considered alongside their use.

AMPLIFY AMPLIFY explores lived experiences to inform how to support individuals using, or having recently stopped using, incretin-based therapies or weight management.

Dr Marie Spreckley @cam.ac.uk leads the AMPLIFY study, exploring the lived experiences of people using, or who have recently stopped, incretin-based weight loss therapies, to better understand how to support them with information and wrap-around support.

Find out more at buff.ly/AxR0QqR

(2/2)